BMFTR funds project to translate CRISPR technology for innovative cancer research

Prof. Frank Buchholz 's laboratory receives federal funding for the "CanCorrect" project. The project, which is funded by the BMFTR, focuses on the development of optimized adenine base editors (ABEs) for precise genome editing of driver mutations in cancer cells. Preliminary results show promising potential in correcting specific mutations and inhibiting tumor growth without undesirable side effects.

With this project, the research group will conduct further experiments to validate the efficacy and safety of ABE systems in correcting cancer "hotspot" mutations, which in turn may lead to significant advances in personalized cancer therapy and precision medicine, as it promises more accurate diagnoses and opens up new therapeutic options for cancer patients. This technology paves the way for innovative, customized cancer therapies and the clinical implementation of genome editing.

Background

The BMFTR funding program "Validation of the technological and social innovation potential of scientific research - VIP+" supports researchers in taking the first step from the world of research towards economic value creation or social application. With VIP+, this further research and development work is funded in projects of up to three years with up to 1.5 million euros.

To the project